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Arthur Kavanaugh7, Katherine C. Saunders2, Ying Shan2, Tanya M. Spruill8, Dimitrios A. Pappas2,9
and Jeffrey D. Greenberg2,8
Abstract
Background: Factors associated with care concordant with the American College of Rheumatology (ACR)
recommendations for the use of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA)
are unknown.
Methods: We identified a national cohort of biologic-naive patients with RA with visits between December 2008
and February 2013. Treatment acceleration (initiation or dose escalation of biologic and nonbiologic DMARDs) in
response to moderate to high disease activity (using the Clinical Disease Activity Index) was assessed. The
population was divided into two subcohorts: (1) methotrexate (MTX)-only users and (2) multiple nonbiologic
DMARD users. In both subcohorts, we compared the characteristics of patients who received care consistent with
the ACR recommendations (e.g., prescriptions for treatment acceleration) and their providers with the characteristics
of those who did not at the conclusion of one visit and over two visits, using logistic regression and adjusting for
clustering of patients by rheumatologist.
Results: Our study included 741 MTX monotherapy and 995 multiple nonbiologic DMARD users cared for by 139
providers. Only 36.2 % of MTX monotherapy users and 39.6 % of multiple nonbiologic DMARD users received care
consistent with the recommendations after one visit, which increased over two visits to 78.3 % and 76.2 %,
respectively (25–30 % achieved low disease activity by the second visit without DMARD acceleration). Increasing
time since the ACR publication on RA treatment recommendations was not associated with improved adherence.
Conclusions: Allowing two encounters for treatment acceleration was associated with an increase in care
concordant with the recommendations; however, time since publication was not.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease that affects an estimated 1.3 million Americans [1].
Given the morbidity and mortality associated with the
condition, current recommendations are that patients
receive early and aggressive treatment with the goal of
preventing joint damage and deformity as well as func-
tional impairment [2, 3]. Treating to a certain target
level of disease activity, usually remission or low disease
activity, is an approach that has gained international
support [4]. In the United States, the American College
of Rheumatology (ACR) published recommendations in
2008 and updated them in 2012 to provide evidence-based
guidance on the optimal use of biologic and nonbiologic
disease-modifying antirheumatic drugs (DMARDs and
nbDMARDs, respectively) [5, 6].
However, despite the increasing attention to escalating
therapy for RA in the setting of active disease, prior
work has shown that only approximately 50 % of
patients receive the recommended medications and that
publication of the 2008 ACR recommendations did not
improve this rate [7]. It is not clear why the rate is so
low. Providing care consistent with the treatment rec-
ommendations is a complex behavior, as it relies both on
physicians to prescribe the medications and on patients
to agree to take these agents. Specifically, physicians
need to be aware of the treatment recommendations,
agree with the approach, and suggest it to their patients
[8]. Then patients need to be receptive to this approach,
as well as to have the resources and the resolve to take
the recommended medications. We proposed to explore
the impact of the diffusion of the ACR recommendations
over time by evaluating trends in the proportion of
patients receiving concordant care in the years since the first
ACR publication. Additionally, we sought to characterize
the patients who do not receive the recommended care and
their treating providers so that these subgroups could be
targeted for further intervention. Specifically, we iden-
tified a cohort of biologic-naive patients with RA with
active disease and their treating providers using data
from the Corrona, LLC, registry, looking at prescribed
medication changes. The aim of this study was to examine
the factors associated with receipt of care consistent with
the recommendations with the hypothesis that, over time,
the majority of patients would be likely to receive the
recommended care.
Methods
Data sources and data collection
The Corrona registry includes a prospective U.S. obser-
vational cohort of patients with arthritis who are en-
rolled by participating rheumatologists in both academic
and private practice sites [9, 10]. Data are collected from
both patients and their treating rheumatologists, who
gather information on disease duration, prognosis,
disease severity and activity, medical comorbidities, use
of medications including DMARDs, and adverse events
[11]. Follow-up assessments are requested at least as
often as every 6 months (mean is 4 months) and com-
pleted during routine clinical encounters. Approvals for
participation in the Corrona registry are obtained from
the respective institutional review boards of participating
academic sites and a central institutional review board
(New England Institutional Review Board) for private
practice sites, and patients provide informed consent
before enrollment.
Study population
There were 36,036 enrolled patients with RA and
237,954 visits entered into the Corrona registry database
for this population between 1 December 2008 and 25
February 2013. Over 150 rheumatology practices enroll
patients across 40 states with 550 participating rheuma-
tologists. There are no disease activity requirements or
comorbidity exclusion criteria. We selected patients who
were biologic-naive, had an index visit and a follow-up
visit within 6 months with rheumatologists (not midlevel
providers), a disease duration longer than 1 year, and
were not in remission or did not have low disease activity
based on the Clinical Disease Activity Index (CDAI ≤10.0).
The patients were further divided into two separate
subcohorts based on their history of treatments and
current medications at the baseline index visit: (1)
methotrexate (MTX) monotherapy users, defined as those
currently on MTX or who had used MTX in the past
without past or current use of other nbDMARDs; and (2)
multiple-nbDMARD users, defined as those who were
receiving or had received two or more nbDMARDs. This
strategy was employed to allow comparison with the ACR
treatment recommendations, which are based on prior
medication use.
Measures
We calculated the CDAI for patients and stratified them
by CDAI score into moderate or high disease activity
levels at the baseline visit [12]. As the 2008 ACR treat-
ment recommendations suggest different treatment
strategies based on prognosis, we evaluated the progno-
sis in patients as defined. Specifically, the prognosis was
determined to be “good” or “poor” based on the absence
or presence of a modified Health Assessment Question-
naire (mHAQ) greater than 0.5 at the initial visit, rheuma-
toid factor positivity, presence of extraarticular disease
(rheumatoid nodules or secondary Sjögren’s syndrome),
and erosive changes on an x-ray. To allow comparisons
with the ACR treatment recommendations, those with
moderate disease activity in the MTX monotherapy
cohort were stratified further on the basis of prognosis
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(any features of poor prognosis present vs. all absent), with
these analyses performed only with those with a poor
prognosis.
DMARD prescribing patterns
We characterized DMARD prescribing patterns in terms
of dose escalation or initiation of biologic and nonbiolo-
gic DMARDs. This was examined at the conclusion of
one visit and over two visits. First, we assessed treatment
practices based on the conclusion of the baseline visit
(the first visit within the time period of interest). We
then assessed whether treatment was accelerated, de-
fined as dose escalation or DMARD initiation (biologic
or nonbiologic), which was considered consistent with
the recommendation. If treatment was accelerated, this
was categorized into one of three treatment regimens as
follows: (1) biologic DMARD initiated, (2) nbDMARD
initiated, and (3) nbDMARD dose increased. Second,
we identified disease activity and medication changes
at both the baseline visit and the follow-up visit (a visit at
least 3 months and up to 6 months after the baseline visit)
over the period of the two visits. In this manner, we identi-
fied whether patients received treatment consistent with
the ACR treatment recommendations. For evaluation of
concordance, we first examined whether treatment was
accelerated at the baseline visit, which was considered
consistent with the recommendations (Table 1). Then we
included treatment acceleration over the two-visit period
or achievement of low disease activity at the second visit
in those who did not accelerate therapy as being consist-
ent with the recommendations (Table 1) [5].
Statistical analysis
The demographic and clinical characteristics of patients
(e.g., age, sex, marital status, insurance type, work status,
RA disease duration, disease activity, concomitant medi-
cation, and functional impairment) and their treating
rheumatologists (e.g., years in practice, sex, practice set-
ting, and geographical location) were compared on the
basis of receipt of care consistent with the recommenda-
tions. We were unable to evaluate the role of white vs.
black vs. Asian vs. other race/ethnicity, given the con-
founding of characteristics by site and that some sites
have mostly nonwhite patients enrolled and others have
mostly white patients enrolled. For continuous variables,
means and SDs were estimated and t tests were used to
test statistical differences between the groups. For
dichotomous variables, percentages were estimated and
χ2 tests or Fisher’s exact tests were used to test statistical
differences between groups as appropriate. We com-
pared the patient and provider characteristics associated
with care consistent with the ACR recommendations
using a mixed effects logistic regression approach and
considering clustering of patients within physicians as a
random effect. To evaluate whether time period since
publication of the ACR recommendations influenced the
results, we included in the models variables representing
the 4 years of the study period (1 December 2008 to 30
November 2009, 1 December 2009 to 30 November
2010, 1 December 2010 to 30 November 2011, and 1
December 2011 to 28 February 2013). Statistical analyses
were performed using STATA version 11.1 software
(StataCorp, College Station, TX, USA).
Results
There were 36,036 patients with RA (Fig. 1), of whom
1736 met the criteria for inclusion in this cohort (741
MTX monotherapy users and 995 multiple-nbDMARD
users). There were 139 treating rheumatologists. The
baseline characteristics of the patients and their treating
rheumatologists are shown in Table 2. Among the
MTX monotherapy users, the mean age was 66 years,
the mean disease duration was 10 years, and the mean
CDAI of 21 (CDAI moderate disease activity 10.1–22).
At the first visit, the median dose of MTX was 17.5 mg
(interquartile range [IQR] 15–20). The treating rheuma-
tologists (n = 106) were usually male, in a private practice
setting, and clinically active for 3 decades. Most practice
Table 1 Evaluation of treatment approaches in comparison with ACR treatment recommendation
First visit Second visit
Disease activitya Treatment
acceleration
Consistent with
recommendationsb
Disease activity Treatment
acceleration
Consistent with
recommendationsc
Active Yes Yes Active Yes or no Yes
Not active Yes or no Yes
Active No No Active Yes Yes
Active No No
Not active Yes or no Yes
aActive disease is moderate disease activity with poor prognosis (modified Health Assessment Questionnaire >0.5, presence of rheumatoid nodules, erosive
changes on x-ray, rheumatoid factor-positive, and secondary Sjögren’s syndrome) or high disease activity in the methotrexate monotherapy users and moderate
or high disease activity in the multiple nonbiologic disease-modifying antirheumatic drug users
bCompliant with the recommendations in the cross-sectional analysis
cCompliant with the recommendations over the first and second visits in the longitudinal analysis
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sites were in the Northeast, with the fewest sites in the
West. Among the multiple-nbDMARD users, the mean
age was 63 years, mean disease duration of 13 years,
and mean CDAI of 19. Coming into the first visit, 47.2 %
were taking one nbDMARD, 39.8 % were taking two
nbDMARDs, and 3.7 % were taking three nbDMARDs.
There were 92 (9.3 %) who were not currently taking
DMARDs. The treating rheumatologists (n = 125) were
usually male, in private practice, with 3 decades of experi-
ence, and mostly in the Northeast, South, and Midwest.
Unadjusted rates of concordance with treatment
recommendations
When we evaluated concordance at the conclusion of
the first visit, we found that 36.2 % of MTX monother-
apy users (n = 268) and 39.6 % of multiple-nbDMARD
users (n = 394) received treatment acceleration, which is
consistent with the recommendations. Specifically, in the
MTX monotherapy users for whom treatment was acceler-
ated, a biologic was added in 91 (34.0 %), an nbDMARD
was initiated in 72 (26.9 %), and the MTX was increased
for 105 (39.2 %). Similarly, among the multiple-nbDMARD
users for whom treatment was accelerated, a biologic was
initiated in 143 (36.3 %), an nbDMARD was initiated in 99
(25.1 %), and the nbDMARD dose was increased in 152
(38.6 %). When we examined care over two visits in the
longitudinal analysis, we found that the rates of concordant
care increased to 78.3 % in MTX monotherapy users and
76.2 % among multiple-nbDMARD users. Specifically in
the MTX monotherapy users, in addition to the 36.2 %
who had treatment acceleration at the first visit, an
additional 11.6 % of users had treatment acceleration
at the second visit. Of note, 30.5 % (n = 226) no longer
had active disease despite no intensification of therapy. In
this subgroup, most were female (70 %), the mean age was
69 years (±12.5), and the median duration of RA was
Fig. 1 Flowchart depicting the study cohort. MTX methotrexate, RA rheumatoid arthritis, nbDMARD nonbiologic disease-modifying antirheumatic
drug. *Prior or current use of methotrexate only as nonbiologic DMARD. **Prior or current use of 2 or more nonbiologic DMARDS. ***For the
MTX monotherapy group, limited to patients seen with moderate disease activity and poor prognosis or high disease activity and seen by a
physician (not a midlevel provider) at both visits. For the multiple nonbiologic DMARD group, included only those patients with moderate or high
disease activity seen by a physician (not a midlevel provider) at both visits
Table 2 Baseline characteristics of the two cohorts and their
treating rheumatologists
MTX monotherapy
users
Multiple nonbiologic
DMARD users
Patient characteristics, n 741 995
Demographics
Age, years, mean (SD) 65.8 (12.4) 63.3 (11.9)
Sex, % female 74 % 81 %
White, % 83 % 83 %
Insurance, %
Private 64 % 66 %
Medicare 46 % 49 %
Medicaid 9 % 7 %
Clinical
Disease duration,
years mean (SD)
10.4 (9.7) 12.7 (10.6)
mHAQ, mean (SD) 0.6 (0.5) 0.5 (0.5)
CDAI, mean (SD) 20.8 (10) 19.0 (9.9)
Ever use of prednisone, % 40 % 54 %
Provider characteristics, n 106 125
Years in practice, mean (SD) 31 (9.2) 30.5 (9.9)
Sex, % male 88 % 79 %
Practice setting
Academic 4 % 10 %
Private practice 96 % 90 %
Location
Northeast 48 % 29 %
South 25 % 30 %
Midwest 18 % 33 %
West 9 % 8 %
CDAI Clinical Disease Activity Index, mHAQ modified Health
Assessment Questionnaire
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6.5 years (IQR 3–18). At the time of the first visit, the me-
dian physician global assessment was 24.5 (IQR 12–35),
the median CDAI was 15.4 (IQR 11.9–20.7), and the
median swollen joint count (SJC) was 5 (IQR 2–8). Be-
tween visits, 17 (7.5 %) of the 226 patients either added or
escalated prednisone therapy and 141 (62.3 %) reported
nonsteroidal anti-inflammatory drug (NSAID) use. For
the multiple-nbDMARD subcohort, in addition to the
39.6 % who had treatment acceleration at the first visit, an
additional 11.9 % had treatment acceleration at the second
visit. Of note, 24.7 % (n = 246) no longer had active disease
despite no intensification of therapy. These 246 patients
were mostly women (78 %), had a median age of 65 years
(IQR 72–57), and median disease duration of 10 years
(IQR 6–20). At the first visit, the median physician
global assessment was 20 (IQR 14–30), the median
CDAI was 13.0 (IQR 11.2–16.0), and the median SJC
was 3 (IQR 2–6). Prednisone use was initiated or
escalated in 22 (8.9 %) of the 246 patients and NSAID
use was reported by 150 patients (60.1 %). Among
the MTX monotherapy and multiple-nbDMARD pa-
tients whose treatment was not accelerated despite
active disease, two-thirds had a visit 6 months or less
before the first study visit. In those MTX monotherapy
users, none had a dose change between this prior visit and
the first visit in the study. In the multiple-nbDMARD
patients, only 5 % had an increase in their dosages over
the time between the prior visit and the first study visit.
Examination of factors associated with concordance in
adjusted analyses
At the conclusion of the first visit, in adjusted analyses,
patient factors associated with care consistent with the
recommendations among MTX monotherapy users
included high disease activity (OR 1.85, 95 % CI 1.29–
2.66) (Table 3). Among patients who received multiple
nbDMARDs, higher disease activity (OR 1.67, 95 % CI
1.23–2.26), more recent disease onset (for each increase
of 5 years, OR 0.85, 95 % 0.79–0.91) and residing in the
Midwest (OR 1.67, 95 % CI 1.18–2.37) were associated
with care consistent with the treatment recommenda-
tions. In the adjusted analyses examining care over two
visits, having private insurance (OR 1.59, 95 % CI 1.06–
2.39) and residing in the South (OR 2.76, 95 % CI 1.42–
5.36) were associated with concordance with the recom-
mendations among MTX monotherapy users (Table 4).
Among the multiple-nbDMARD users, work status
(OR 1.94, 95 % CI 1.27–2.95) and more recent disease
onset (for each increase of 5 years, OR 0.89, 95 % CI
0.83–0.96) were associated with care consistent with the
guidelines. There was no improvement over time in terms
of concordance to the recommendations in either the
unadjusted or adjusted cross-sectional and longitudinal
models in the two cohorts.
Discussion
In this sample of patients within the largest U.S. registry
of patients with RA with data capture from both patients
and physicians, receipt of care consistent with the
treatment recommendations occurred in 36–40 % at the
conclusion of a single visit but rose to approximately
76–78 % when treatment decisions over two visits were
examined (45 % had treatment acceleration and 30 % no
longer had active disease). There was no increase in the
rates of concordant care over the 4 years since publication
of the recommendations. Patient factors such as disease
duration, disease activity, work status, and insurance
coverage, as well as specific U.S. regions, were associated
with care consistent with the recommendations.
At the conclusion of the first visit, in the adjusted
analyses, patient factors associated with high disease ac-
tivity and poor prognosis strongly influenced treatment
patterns in the MTX monotherapy and multiple-
nbDMARD users. It is not surprising that none of the
specific physician factors influenced the care approach,
given the consensus that MTX should be considered
first-line therapy for those with active disease [5, 6]. In
Table 3 Adjusted likelihoods of receiving care concordant with
the recommendations at a single visita
MTX monotherapy
users (n = 741)
Multiple nbDMARD
users (n = 995)
Patient factors
High disease activity
(vs. moderateb)
1.85 (1.29–2.66) 1.67 (1.23–2.26)
Disease duration
(per 5 years)
0.95 (0.87–1.05) 0.85 (0.79–0.91)
Provider factors
Geographic region
Northeast (reference) 1 1
South 1.14 (0.63–2.07) 1.23 (0.86–1.77)
Midwest 1.56 (0.82–2.97) 1.67 (1.18–2.37)
West 1.92 (0.83–4.42) 1.06 (0.61–1.82)
Time period
December 2008–
November 2009 (reference)
1 1
December 2009–
November 2010
0.81 (0.52–1.28) 1.15 (0.82–1.62)
December 2010–
November 2011
1.09 (0.70–1.71) 0.86 (0.59–1.26)
December 2011–
February 2013
0.71 (0.42–1.19) 0.76 (0.50–1.14)
aAdjusted for age, sex, work status, prednisone use, practice years, and time
period, although none significantly associated as well as clustering of patients
within physician. Patient race/ethnicity (white vs. black vs. Asian vs. other) was
included in the models but could not be evaluated, owing to confounding of
this characteristic by site
bHigh disease activity was compared with moderate disease activity with a
poor prognosis for the methotrexate (MTX) monotherapy users and moderate
therapy without regard to prognosis for the multiple nonbiologic disease-
modifying antirheumatic drug (nbDMARD) users
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contrast, among patients receiving multiple nbDMARDs,
geographic region was related to treatment patterns.
While treatment recommendations suggest equal aggres-
siveness in those patients who are not responding to one
vs. two nbDMARDs, this patient population may be a
more diverse and challenging cohort. It is not clear if
this is due to regional differences in RA care, as has been
shown to occur in other countries [13], or if it is related
to differences in patient beliefs and attitudes [8, 14].
When we evaluated factors associated with care over
two visits, patient economic factors played a role in
concordance. Private insurance (MTX monotherapy co-
hort) and work status (multiple-nbDMARDs cohort)
were associated with receipt of care consistent with the
recommendations. Given the high out-of-pocket costs of
healthcare in general and RA medications specifically, it
is not surprising that economic factors play a role in
concordance to the recommendations. In fact, patients
with RA report a higher prevalence of forgoing or
skipping medications due to limited economic means
than do patients with other chronic illnesses [15].
Interestingly, a substantial number of patients achieved
low disease activity between the first and second visits
without treatment acceleration at the first visit. Many of
these patients were at the lower end of the moderate dis-
ease activity range and had only a few swollen joints. The
reduction in disease activity may be related to the natural
history of RA, regression to the mean given we selected
only patients with active disease, and anti-inflammatory
medications such as NSAIDs and prednisone. On the
basis of these findings, more exploration of the risks and
benefits of watchful waiting by physicians and intermittent
use of anti-inflammatories as needed are suggested.
Patients and providers need more evidence to weigh
the impact of close monitoring without an immediate
response, in terms of irreversible damage or a reduced
likelihood of remission, against the costs and potential
side effects of biologics and nbDMARDs. Additionally,
consideration should be given to whether the treatment
recommendations should be revised to suggest treatment
acceleration based on the disease activity trajectory rather
than on a single measurement.
There are numerous barriers to providing care con-
cordant to the treatment recommendation. One is
“clinical inertia,” which is a lack of response to active
disease and has been documented for many other
chronic illnesses [16, 17]. In addition, there are numerous
system-level barriers. These include high copayments
for office visits and medications, as well as the prior
authorization process, which delays access to needed
medication. In addition, most practices are not de-
signed or trained to routinely assess disease activity and
engage in shared decision-making with patients regarding
accelerating medications [18, 19]. Last, patients are often
hesitant to make frequent medication changes [20], even
when indicated.
There are several strengths of this study, including
detailed information on a national cohort of patients
with RA followed by a broad distribution of U.S. rheu-
matologists. However, the study has limitations. We
can identify only treatments that were agreed to by
patients and not those that were offered and declined
[21]. While prescription coverage may have influenced
our results, we minimized that impact by considering
nbDMARD dose escalation and additional nbDMARD
initiation as consistent with the recommendations [22–24].
While we examined a national cohort of patients cared
for by almost 200 physicians, they may not be represen-
tative of the total RA patient population and rheuma-
tologists across the United States in terms of clinical
characteristics and RA treatment practices. However,
prior work using national Medicare data showed that
patients with RA enrolled in the Corrona registry are
more likely than those not enrolled to receive DMARDs,
suggesting that our results are overestimates rather
than underestimates of concordant care across the
United States [25].
Table 4 Adjusted likelihood of receiving care concordant with
the recommendations over two visitsa
MTX monotherapy
users (n = 741)
Multiple-nbDMARD
users (n = 995)
Patient factors
Work status 1.28 (0.79–2.09) 1.94 (1.27–2.95)
Private insurance 1.59 (1.06–2.39) 0.93 (0.65–1.33)
Disease duration
(per 5 years)
1.02 (0.92–1.13) 0.89 (0.83–0.96)
Provider factors
Geographic region
Northeast (reference) 1 1
South 2.76 (1.42–5.36) 1.26 (0.75–2.12)
Midwest 0.94 (0.50–1.79) 1.24 (0.72–2.12)
West 1.18 (0.52–2.69) 1.33 (0.61–2.89)
Time period
December 2008–
November 2009
1.00 1.00
December 2009–
November 2010
0.93 (0.56–1.54) 0.79 (0.52–1.20)
December 2010–
November 2011
1.07 (0.63–1.83) 0.85 (0.54–1.36)
December 2011-2/2013 0.85 (0.48–1.51) 0.50 (0.30–0.81)
MTX methotrexate, nbDMARD nonbiologic disease-modifying
antirheumatic drug
aAdjusted for age, sex, baseline disease activity, prednisone use, physician
practice years, and practice type, none of which were significantly associated
with care, as well as clustering of patients by physician. Patient race/ethnicity
(white vs. black vs. Asian vs. other) was included in the models but could not
be evaluated, owing to confounding of this characteristic by site
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Conclusions
This study provides the first detailed assessment of the
factors associated with care consistent with the ACR
treatment recommendations based on prior nbDMARD
use. While concordance to the treatment recommenda-
tions occurred in a little over one-third of patients at the
conclusion of a single visit, it increased to three-fourths
after two visits, in part related to patients with active
disease at the first visit who achieved low disease activity
at the second visit without treatment acceleration.
Importantly, time since publication of the ACR recom-
mendations did not improve concordance, suggesting
that passive dissemination through publication of rec-
ommendations may not be enough to influence care.
Overall, patient characteristics associated with poor
prognosis, economic factors, and geographic region were
associated with care consistent with the recommenda-
tions. To increase concordance to the recommendations,
innovative approaches targeting both rheumatologists
and patients are necessary.
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